Thalidomide and immunomodulatory drugs in the treatment of cancer

Author： Bamias Aristotle Dimopoulos Meletios A

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.14, Iss.1, 2005-01, pp. : 45-55

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Thalidomide Derived Immunomodulatory Drugs (IMiDs) as Potential Therapeutic Agents

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 3, Iss. 3, 2003-09 ,pp. : 181-186

Bentham Science Publishers

Access to resources Recommend Favorite

Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?

Current Cancer Drug Targets, Vol. 18, Iss. 1, 2017-12 ,pp. : 5-15

Bentham Science Publishers

Access to resources Recommend Favorite

Immunomodulatory Drugs (IMiDs™): A New Treatment Option for Myelodysplastic Syndromes

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 5, 2006-10 ,pp. : 339-342

Bentham Science Publishers

Access to resources Recommend Favorite

Thalidomide in Cancer Treatment: A Potential Role in the Elderly?

By Zhou S.

Drugs & Aging, Vol. 19, Iss. 2, 2002-02 ,pp. : 85-100

Adis International

Access to resources Recommend Favorite

Novel and selective immunomodulatory drugs

By Lamont A.G.

Expert Opinion on Emerging Drugs, Vol. 5, Iss. 3, 2000-10 ,pp. : 299-308

Informa Healthcare

Access to resources Recommend Favorite